Zymeworks Inc. - Common Stock (NY:ZYME)

N/A UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Bitcoin Futures Arrive ↗

October 19, 2021

Today you can finally hold Bitcoins via an exchange-traded fund.

Via Talk Markets

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

Markets Boosted ↗

October 07, 2021

Good news helped stock prices.

Via Talk Markets

Perfumes Of Arabia ↗

October 06, 2021

Downtrends do eventually run out of pessimistic steam, but it can take a while.

Via Talk Markets

Sweet Smell Of Recovery ↗

October 05, 2021

Markets today saw many reversals of moves by ADR companies in the course of the day, mainly because of macro changes.

Via Talk Markets

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

October 05, 2021

From Zymeworks Inc.

Via Business Wire

October Starts Positive ↗

October 01, 2021

A lot of these moves are simply reactions to last month's excesses and they may not be predictive for October at all.

Via Talk Markets

Multiple Bits Of Bad News ↗

September 28, 2021

Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.

Via Talk Markets

Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial ↗

September 16, 2021

At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-...

Via Benzinga

Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

September 16, 2021

From Zymeworks Inc.

Via Business Wire

Pressure Day ↗

September 13, 2021

Today a recovery came to markets with a particular impact on uranium shares.

Via Talk Markets

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

September 12, 2021

From Zymeworks Inc.

Via Business Wire

Delta Variant Fears Continue ↗

September 09, 2021

The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher.

Via Talk Markets

The Real World ↗

August 11, 2021

The rise of the delta has caused markets to drop back after the rises earlier although inflation still remains within a point or two of forecasts at 5.3-5.4% annualized.

Via Talk Markets

Delta Outbreak ↗

August 04, 2021

The US market was droopy because of poor private sector jobless numbers.

Via Talk Markets

Zymeworks Reports 2021 Second Quarter Financial Results

August 04, 2021

From Zymeworks Inc.

Via Business Wire

Markets: COVID Is Back ↗

August 03, 2021

BP Plc reported earnings beats of 22 cents with a Q2 eps of 83 cents. Schlumberger Ltd, normally supported by French descendants from the founding Alsatian brothers, was hit by concern about the price...

Via Talk Markets

Topics Earnings

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

August 03, 2021

From Zymeworks Inc.

Via Business Wire

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

July 28, 2021

From Zymeworks Inc.

Via Business Wire

Banned Merger ↗

July 27, 2021

Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood.

Via Talk Markets

Chinese Stock Crash ↗

July 26, 2021

For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on...

Via Talk Markets

Delta Defeats Bulls ↗

July 19, 2021

Stocks tended to crash without rhyme or reason.

Via Talk Markets

Weak Week ↗

July 16, 2021

Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism.

Via Talk Markets

Powell Talks Some More ↗

July 15, 2021

Another day, another sell-off.

Via Talk Markets

Dialing For Stocks ↗

July 14, 2021

Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today.

Via Talk Markets

Topics Economy

Recovery Friday ↗

July 09, 2021

The big winners this week were Financials.

Via Talk Markets

Zymeworks to Present at Ladenburg Thalmann Healthcare Conference

July 08, 2021

From Zymeworks Inc.

Via Business Wire

Fireworks Display ↗

July 05, 2021

The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.

Via Talk Markets

People Needed ↗

July 02, 2021

If qualified people are not looking for work, they will have to be lured to do so with higher wages.

Via Talk Markets

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.